Physician profile
Skye Murray
NPI 1457641169
$2,569.93
in general payments reported to CMS, 2019-2025
26 companies · $974 in 2025
The $974 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $356 · 2022: $27.61 · 2023: $548 · 2024: $664 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $361.07 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $341.84 | 2021-2025 | |
| Abbott Laboratories | $324.24 | 2021-2024 | Aveir, Navitor |
| Boston Scientific Corporation | $236.53 | 2023-2025 | Watchman Flx, Watchman Access System |
| Exactech, INC. | $184.28 | 2023 | |
| Pfizer INC. | $169.04 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $111.44 | 2023-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $102.45 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $89.07 | 2025 | Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.17 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $75.74 | 2021-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $71.00 | 2024 | Arcalyst |
| Heartflow, INC. | $57.70 | 2024-2025 | |
| Bridgebio Pharma, INC. | $56.12 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $43.67 | 2021-2024 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $37.45 | 2021-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.88 | 2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $30.00 | 2025 | Edarbi |
| Sanofi-Aventis U.S. LLC | $27.34 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.90 | 2024 | Evkeeza, Praluent |
| Abiomed | $24.39 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $21.26 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $18.56 | 2025 | |
| Cvrx, INC. | $17.89 | 2024 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $16.54 | 2024 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skye Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.